Cancer drug S-1 shows promise for colorectal cancer but requires careful toxicity monitoring

A new clinical analysis identifies how to safely use the oral fluoropyrimidine S-1 for metastatic colorectal cancer by managing hand-foot syndrome and heart toxicity—two serious side effects that have limited the drug's adoption. The findings could expand treatment options for a disease that kills over 900,000 people annually and unlock market value for pharmaceutical developers.

Originaltitel: Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer